Compare Plby Group Inc (PLBY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plby Group Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Plby Group Inc trades at $1 (market cap $118.21M), while Regeneron Pharmaceuticals Inc trades at $740 (market cap $76.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 644.1× Plby Group Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Plby Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Plby Group Inc for 24 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PLBY | REGN | |
|---|---|---|
Market Cap | $118.21M | $76.14B |
Volume | 919,783 | 500,239 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.71 | $852.03 |
52-Week Low | $0.99 | $557.73 |
Typical Hold Time | 24 Days | 107 Days |
Enterprise Value | $263.80M | $70.85B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PLBY Group trades at $1.02, down 1.92% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue stabilizing around $120-125 million and net losses narrowing significantly from -$278 million in 2022 to -$13 million in 2025. Recent management appointments aim to drive brand growth, while positive operating cash flow in 2025 and projected profitability in 2026 signal potential turnaround.
While analyst consensus remains strongly bullish (75% buy ratings), the stock faces headwinds from high debt levels and negative shareholder equity. The path to sustainable profitability remains the key catalyst, with current valuation metrics suggesting cautious optimism if execution improves. Near-term price action appears range-bound near support levels.
Regeneron Pharmaceuticals (REGN) trades at $742.12, up 0.46% on the day, with a bearish technical signal despite strong fundamentals. The stock shows robust profitability with a 27.86% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront and milestone payments.
The outlook is positive due to strong earnings momentum and strategic collaborations, but risks include competitive pressures in key drug markets and technical bearish indicators. Analyst consensus is bullish with a $849.84 price target, suggesting potential upside from current levels, though investors should monitor execution of new partnerships and pipeline developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
